Trial Profile
A Prospective, Multicenter, Single Arm Trial Evaluating the BARD Lutonix Drug-Coated Balloon (LTX DCB) for Treatment of Femoropopliteal Arteries (LEVANT China)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 21 Jan 2021
Price :
$35
*
At a glance
- Drugs Paclitaxel (Primary)
- Indications Peripheral arterial disorders
- Focus Adverse reactions; Therapeutic Use
- Acronyms LEVANT China
- Sponsors C.R. Bard
- 19 Jan 2021 Status changed from active, no longer recruiting to completed.
- 21 Apr 2020 Planned End Date changed from 1 Oct 2019 to 1 Aug 2020.
- 31 Jan 2019 Planned End Date changed from 1 Sep 2019 to 1 Oct 2019.